Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma

NCT00896493 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT00896493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00896493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
December 31, 2022
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow transplant failure, cutaneous t-cell lymphoma, lymphoma, non-hodgkin, lymphoma, t-cell, cutaneous, mycoses, sezary syndrome